Our growing management team combines a depth of biotechnology and pharmaceutical knowledge with superb hands-on business experience.

Steven Kelly, President & CEO
J. Gregory Jester, Vice President & Chief Financial Officer
Eric E. Poma, Ph.D., Vice President of Business Development

Steven Kelly, President & CEO
Steven Kelly brings more than fifteen years experience in a variety of commercial roles in biotechnology and pharmaceutical companies.

Prior to joining Innovive, Mr. Kelly headed the newly created oncology marketing group for Sanofi-Synthelabo’s US division, where he led the launch of Eloxatin™, the pharmaceutical industry’s most successful anti-cancer product launch to date. Mr. Kelly joined Sanofi from IDEC Pharmaceuticals, where, in a co-promotion agreement with Genentech, he led the launch of Rituxan®, now one of the leading anticancer therapies in the U.S. Prior to IDEC, Mr. Kelly worked at Amgen, where he held various positions, including roles in Epogen® marketing, new products marketing, and manufacturing.

Mr. Kelly holds an MBA from Cornell University and a BS, Biology and Chemistry from the University of Oregon.

J. Gregory Jester, Vice President & Chief Financial Officer
Mr. Jester joined Innovive in October 2006 as Vice President and Chief Financial Officer. Prior to joining Innovive, from 1995 to 2006, Mr. Jester was employed by Barr Pharmaceuticals, Inc. most recently as Vice President and Corporate Controller where he led a 40 person team responsible for corporate and operational accounting, financial reporting and analysis, budgeting and forecasting as well as all SEC filings. Prior to Barr, Mr. Jester held various positions at Meridian Sports Inc., The CIT Group/Credit Finance and KPMG LLP. Mr. Jester is a Certified Public Accountant and received his B.S., Business Administration from the University of Richmond.

Eric E. Poma, Ph.D., Vice President of Business Development
Dr. Poma most recently served as Assistant Vice President, Business Development for ImClone Systems, Inc., where he was responsible for all licensing and partnership agreements. Dr. Poma also ran the Strategic Planning group at ImClone prior to his appointment to Business Development. Prior to Imclone, Dr. Poma was a Healthcare and Biotechnology analyst for Eagle Growth Investors and held a variety of positions at Bates Healthworld (marketing and contract sales), Rood Research (market research) and Cline, Davis & Mann (pharmaceutical advertising).

Eric Poma earned his PhD in Microbiology and Immunology from the University of North Carolina at Chapel Hill, School of Medicine. He holds an MBA from the Leonard N. Stern School of Business at New York University and a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill.